MBRX Latest Headlines

Moleculin Highlights Non-Cardiotoxic Profile of Lead Annamycin Drug

at www.tipranks.com (Tue, 13-Jan 9:34 AM)

Moleculin Biotech advances Annamycin AML Phase 3 program

at www.tipranks.com (Mon, 12-Jan 9:06 AM)

Moleculin Raises $6.5 Million from Warrant Exercises—Fresh Capital and New Warrants Set the Stage for 2026

Market Chameleon (Wed, 10-Dec 9:02 AM)

Moleculin’s New Annamycin Brain Tumor Collaboration Targets Unmet Needs in Glioblastoma

Market Chameleon (Mon, 8-Dec 8:48 AM)